‘This is a sign of the times’: How pharma’s outsourcing strategy is changing

The global pharmaceutical industry has a long history of outsourcing research and development.

The most famous example is the development of the polio vaccine, but there are plenty of other examples of outsourcing and even the outsourcing of clinical trials.

A recent report by the New York-based consultancy firm Avalere and the University of Pennsylvania’s Wharton School says pharma is using more outsourcing than ever.

This year, the firm said more than 3.6 million of its healthcare companies will use the “bulk purchasing” strategy to spend $5.7 trillion.

It estimates that global outsourcing has increased by more than 50% since 2010, when it started using bulk purchasing.

The report also found that, while pharma companies have traditionally spent a lot of money on clinical trials, the pace of spending is now “significantly faster than it has been for the last two decades”.

The report, The Burden of Drug Prices, says bulk purchasing will continue to grow, but the pace will be “signaling a shift towards greater reliance on clinical trial data” and will be accompanied by a “shrinking proportion of the industry’s total spending on research and developing technologies”.

The Wharton report, commissioned by Avalere, estimates that bulk purchasing has increased from $11.7 billion in 2015 to $19.5 billion in 2019.

It says that since 2010 the bulk buying strategy has seen an increase in spending on R&D and clinical trial-related research and the total amount of money spent on research has increased “by more than a quarter”.

While the bulk purchasing strategy has increased in recent years, it is still more than 80% of total pharmaceutical spending.

And it is not just bulk purchasing that is increasing.

The Whartons report found that the average amount of research spending by pharma has gone up by about a third since 2010.

But there has been a dramatic change in how the bulk spending is spent.

In 2019, the bulk-buying strategy accounted for about 60% of the total pharmaceutical industry spending.

By 2020, that figure had increased to 72%.

The Wharts report says that bulk-spending has increased, but that it is largely due to the outsourcing model, where companies buy and deliver drugs to customers and then test them on patients.

This is happening at a slower pace than the bulk procurement strategy, which is seeing a similar shift to what happened when the bulk purchase strategy was introduced.

In the early days of bulk purchasing, drugs were tested in clinical trials and patients were enrolled in clinical studies.

However, bulk procurement has been used by a lot more than just pharmaceutical companies.

The New York Times reports that bulk procurement accounts for about 80% to 90% of all pharmaceutical spending worldwide.

Wharton researchers have calculated that the bulk price of a generic drug can increase by more then 40% for every 100,000 dollars that a generic version costs.

The bulk price for a generic of a drug will be higher for a patient who does not have insurance.

It will be about 80-90% higher for people with pre-existing conditions.

There has also been a significant rise in the price of generic drugs.

According to Wharton’s calculations, generic drugs have risen by more to more than 500% since 2020.

But the price increases have been concentrated in the US and Europe, and in particular in the UK, where the bulk buy has been especially intense.

It is estimated that about half of all generic drugs sold globally are purchased with bulk procurement, according to Whartones report.

The research and health care industry is in the midst of an overhaul to make it easier for companies to compete with one another and with pharmaceutical companies in other countries.

The industry is also moving away from bulk procurement and into more targeted research.

It was recently reported that the government has asked drug makers to produce a drug that can be used in humans in as little as a few days.

It means that the pharmaceutical companies have to be more efficient in developing new drugs, in terms of the number of doses they need to produce and in the amount of data they have to collect and analyse.

The UK and the US have been among the most successful countries in the world in this effort.

However there is an important caveat with this new system.

While bulk procurement is more efficient, it doesn’t make the drugs that much cheaper.

It does not necessarily mean that the drugs will be cheaper or that the manufacturers will be able to sell them at a higher price, says the report.

In fact, some drugs that are currently priced at around $10,000 are likely to be priced at less than $500.

The researchers also say that while the bulk approach is more economical, it does not provide the same quality of care and the results are still uncertain.

They say that the benefits of bulk procurement are unclear and the cost of clinical trial costs is still unknown.

This isn’t the first time that the drug companies have struggled with the cost and quality of their clinical trials compared with other industries.

A 2014 report by